BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 17666196)

  • 1. Blood pressure lowering only or more? Has the jury reached its verdict?
    Julius S
    Am J Cardiol; 2007 Aug; 100(3A):32J-37J. PubMed ID: 17666196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hypertension in patients with diabetes].
    Poulsen PL; Hansen KW; Gaede PH; Rossing P
    Ugeskr Laeger; 2009 Jun; 171(24):2031-4. PubMed ID: 19523370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective effects of renin-angiotensin blockade beyond blood pressure control.
    Mancia G; Giannattasio C; Seravalle G; Quarti-Trevano F; Grassi G
    J Hum Hypertens; 2009 Sep; 23(9):570-7. PubMed ID: 19190657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The association of hypertension and diabetes: prevalence, cardiovascular risk and protection by blood pressure reduction.
    Mancia G
    Acta Diabetol; 2005 Apr; 42 Suppl 1():S17-25. PubMed ID: 15868115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving blood pressure control and clinical outcomes through initial use of combination therapy in stage 2 hypertension.
    White WB
    Blood Press Monit; 2008 Apr; 13(2):123-9. PubMed ID: 18347448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibiting the renin-angiotensin system: why and in which patients.
    Berra K; Miller NH
    J Am Acad Nurse Pract; 2009 Jan; 21(1):66-75. PubMed ID: 19125897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Success of blood pressure reduction in diabetic patients].
    Schernthaner G
    Dtsch Med Wochenschr; 2006 Dec; 131 Suppl 8():S247-51. PubMed ID: 17139580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antihypertensive strategy based on angiotensin II receptor blockers: a new gateway to reduce risk in hypertension.
    Tocci G; Sciarretta S; Facciolo C; Volpe M
    Expert Rev Cardiovasc Ther; 2007 Jul; 5(4):767-76. PubMed ID: 17605654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reaching for aggressive blood pressure goals: role of angiotensin receptor blockade in combination therapy.
    Milani RV
    Am J Manag Care; 2005 Sep; 11(7 Suppl):S220-7. PubMed ID: 16180960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lessons in hypertension from new clinical trials.
    Nesbitt SD
    Postgrad Med; 2009 Nov; 121(6):34-43. PubMed ID: 19940415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fixed-dose combinations of renin-angiotensin blocking agents with calcium channel blockers or hydrochlorothiazide in the treatment of hypertension.
    Bramlage P
    Expert Opin Pharmacother; 2009 Aug; 10(11):1755-67. PubMed ID: 19538001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New onset diabetes during antihypertensive therapy.
    Alderman MH
    Am J Hypertens; 2008 May; 21(5):493-9. PubMed ID: 18437139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
    Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin receptor blockade in the challenging era of systolic hypertension.
    Stergiou GS
    J Hum Hypertens; 2004 Dec; 18(12):837-47. PubMed ID: 15318161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current possibilities of ACE inhibitor and ARB combination in arterial hypertension and its complications.
    Kolasinska-Malkowska K; Filipiak KJ; Gwizdala A; Tykarski A
    Expert Rev Cardiovasc Ther; 2008 Jun; 6(5):759-71. PubMed ID: 18510491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 'Beyond blood pressure' means multiple risk factor intervention, not pleiotropic antihypertensive drugs.
    Staessen JA; Thijs L; Li Y; Kuznetsova T; Richart T; Wang J; Birkenhäger WH
    Curr Opin Cardiol; 2007 Jul; 22(4):335-43. PubMed ID: 17556887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Oral inhibitors of renin and their potential use as therapeutic agents in treating hypertension].
    Abassi Z; Armaly Z; Nakhoul F; Hoffman A
    Harefuah; 2008 Jun; 147(6):536-42, 573. PubMed ID: 18693632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effects of antihypertensive drugs on glucose metabolism and cardiovascular events].
    Landmark K; Reikvam A
    Tidsskr Nor Laegeforen; 2009 Sep; 129(17):1740-4. PubMed ID: 19756054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of isolated systolic hypertension in diabetes mellitus type 2.
    Os I; Gudmundsdottir H; Kjeldsen SE; Oparil S
    Diabetes Obes Metab; 2006 Jul; 8(4):381-7. PubMed ID: 16776744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.